Dr. Carlos Fernando Valenzuela's lab focuses on understanding how fetal alcohol exposure affects brain development and cognitive function. The research aims to identify the specific mechanisms behind the cognitive deficits caused by fetal alcohol spectrum disorders (FASDs), using advanced techniques like electrophysiology in animal models. Ultimately, the lab seeks to develop targeted treatments to improve outcomes for individuals affected by FASDs.

Dr. Chandra L Muller's research focuses on understanding how education influences cognitive functioning and the risk of Alzheimer's disease and related dementias (AD/ADRD) as people age. By analyzing data from a long-term study that tracked individuals from high school into later life, their lab aims to identify key educational factors that affect cognitive health. This interdisciplinary team combines expertise in neurology, psychology, sociology, and biostatistics to uncover insights that could lead to better interventions for reducing dementia risk.

Dr. Peter Alexander Ljubenkov's lab focuses on finding new treatments for patients with semantic variant primary progressive aphasia (svPPA), a form of dementia closely linked to frontotemporal lobar degeneration. They are conducting a clinical trial to test a drug called Verdiperstat, which may help address the underlying causes of this condition. The lab aims to gather important information about how the drug works and its safety in patients, contributing to future therapies for cognitive disorders related to neurodegeneration.

Dr. Douglas Galasko's lab focuses on research related to Alzheimer's disease, a chronic condition that affects memory and cognition. The lab is currently developing a new drug, GSM-779690, which aims to prevent and slow progress of the disease, particularly in individuals at high genetic risk. This research includes conducting various safety and toxicology studies before advancing to clinical trials.

Dr. Sara N. Burke's lab focuses on understanding how aging affects brain function, particularly how changes in specific brain regions relate to cognitive decline in older adults. With an emphasis on the relationship between individual neurons and brain connectivity, the lab aims to develop interventions that could enhance cognitive abilities in aging populations. They use advanced imaging and neurophysiological techniques to explore these changes in rats, which can provide insights into human cognition as well.

Dr. Byoung-Il Bae's laboratory focuses on understanding how the human brain develops, particularly the large and folded areas of the cerebral cortex that are different in humans compared to mice. They investigate the role of a gene called ASPM, which when lost leads to brain disorders like microcephaly. Using innovative animal models such as ferrets and advanced technologies, their research aims to reveal how unique developmental processes in gyrencephalic mammals contribute to human brain health and disease.

Dr. Matthew Barrett's research lab focuses on understanding cognitive fluctuations in Lewy body dementia, a common but poorly understood symptom causing unpredictable lapses in attention and alertness. The lab investigates how degeneration of cholinergic neurons in the brain contributes to these cognitive impairments and evaluates potential therapeutic interventions. By combining imaging techniques with cognitive assessments, the lab aims to develop new strategies to better monitor and treat patients suffering from this condition.

Dr. Francine Grodstein's lab at Rush University focuses on understanding cognitive health and aging, particularly in diverse populations like Mexican-Americans and African Americans. The lab conducts rich studies looking at genetics and socioeconomic factors in relation to cognitive impairment and healthcare utilization in older adults. The goal is to improve our understanding of Alzheimer's disease and related conditions, guiding better healthcare strategies and interventions for affected individuals.

Dr. Alice S Chen-Plotkin's research focuses on understanding the differences in cognitive outcomes among patients with Lewy body diseases, which include Alzheimer's disease and Parkinson's disease. By studying the role of a protein called alpha-synuclein and its interactions with other disease markers, her lab aims to identify why some patients experience significant cognitive decline while others do not. The ultimate goal is to uncover new therapeutic targets to help manage or prevent these debilitating diseases.

Dr. David J. Clark's lab at the University of Florida focuses on finding new ways to help older adults maintain their cognitive and walking abilities. The lab studies how combining physical exercise with brain stimulation can improve brain function and prevent decline associated with aging. They aim to create effective interventions that specifically target brain areas involved in thinking and walking, which can enhance overall mental and physical health in older adults.

Dr. Marion Buckwalter's lab focuses on understanding how blood-brain barrier dysfunction contributes to cognitive decline in patients who have experienced a stroke. They investigate the long-term effects of stroke on brain health, specifically how inflammation and vascular changes may lead to post-stroke dementia. The lab aims to develop biomarkers that help predict which stroke survivors are at risk for cognitive impairment, paving the way for better management and treatment strategies.

Dr. Laura Thi Germine's lab at Albert Einstein College of Medicine focuses on improving mental health outcomes for individuals with serious mental illnesses. The lab develops innovative cognitive measures that track people's mental processes over time to predict clinical risks and treatment needs more effectively. Their work aims to make mental health care more accessible and culturally appropriate through the use of technology and comprehensive data analysis.

Dr. Maria Luisa Gorno Tempini's research focuses on improving the diagnosis and monitoring of Alzheimer's disease and frontotemporal dementia, particularly among Latino and English-speaking populations. Using innovative automated speech and language analysis techniques, her lab aims to identify specific markers of cognitive decline across diverse socio-biological backgrounds. This research not only addresses the inequities in dementia assessment but also strives to develop cost-effective, culturally sensitive diagnostic tools that can benefit underrepresented communities.

Dr. Felicia C. Chow's lab focuses on understanding how sexual differences influence neurocognitive impairment and recovery in people living with HIV, alongside improving diagnostic methods for tuberculous meningitis. By studying the impacts of cerebrovascular health and immune responses, her research aims to develop better treatments tailored to men and women. Moreover, her lab is dedicated to enhancing research capacity in regions heavily affected by tuberculosis, fostering local expertise for more effective health interventions.

Dr. Simon Henin's lab at NYU focuses on understanding how our brains learn from experiences using statistical learning, a key process in acquiring language and other cognitive skills. By combining advanced imaging techniques with direct recordings from the brains of patients, the lab aims to reveal how different regions of the brain, particularly the cortex and hippocampus, interact while we learn. This research could lead to new insights and therapies for cognitive deficits associated with neurological disorders.

Dr. Kan Ding's lab focuses on understanding the effects of traumatic brain injury (TBI) on cognitive function and its relationship with cerebrovascular health. They investigate how early cerebrovascular dysfunction after TBI impacts cognitive recovery and the risk of long-term neurodegenerative conditions like Alzheimer's disease. Through longitudinal studies, they aim to identify mechanisms to improve cognitive outcomes for TBI survivors.

Dr. Paul E. Schulz's lab focuses on understanding how COVID-19 affects the brain, specifically investigating the long-term cognitive dysfunction that some patients experience after their recovery. They explore factors such as patient demographics and underlying inflammation that might influence cognitive decline. The lab collects data from a diverse group of individuals who were hospitalized with COVID-19, aiming to develop better treatments for those suffering from neurocognitive issues post-infection.

Dr. Mellanie V Springer’s lab focuses on understanding the cognitive challenges faced by stroke survivors, particularly the risk of Vascular Cognitive Impairment and Dementia (VCID). The team investigates how everyday activities like reading and solving puzzles can help protect brain health after a stroke. They also explore the impact of sleep disorders, such as obstructive sleep apnea, on cognitive decline in stroke patients. By identifying modifiable factors, the lab aims to develop practical interventions to improve cognitive outcomes for stroke survivors.

Dr. Greg A. Gerhardt's lab at the University of Kentucky focuses on developing new treatments for cognitive decline associated with Alzheimer's disease and related dementias. They conduct clinical trials using cell therapy techniques, specifically delivering nerve tissue to repair neural circuits that are affected in these diseases. The lab's research aims to enhance the function of cholinergic neurons in patients with Alzheimer's and related conditions, potentially offering more than just symptom relief.

Dr. Emily Rogalski leads a research lab at the University of Chicago focused on understanding cognitive resilience in aging and improving communication for individuals with neurological conditions. Her work aims to identify factors that contribute to exceptional cognitive performance in older adults, particularly those who are 'SuperAgers.' Additionally, she develops interventions to enhance the quality of life for patients with primary progressive aphasia, exploring both clinical trials and community-based solutions.